A Phase I study reported that natural killer (NK) cell infusions produced promising signals in patients with recurrent hepatocellular carcinoma after liver transplantation. Investigators led by Yang and colleagues evaluated safety and early efficacy in a difficult‑to‑treat, immunosuppressed population and observed tolerability alongside hints of antitumor activity. The trial addresses a critical unmet need: recurrent HCC post‑transplant has limited options because of graft tolerance and immunosuppression. NK cell therapy offers an innate immune approach that may avoid graft rejection while targeting residual tumor cells. The study remains early and small, focusing on dose escalation and safety endpoints. If subsequent trials confirm safety and activity, NK‑based adoptive therapies could provide a bridge for transplant recipients who cannot tolerate checkpoint inhibitors or cytotoxic regimens.